Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a highly specific and significant imaging target for malignancies.
[68Ga]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in the diagnosis and research of a wide variety of PSMA high-expression malignanciesr.
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a highly specific and significant imaging target for malignancies.[68Ga]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in the diagnosis and research of a wide variety of PSMA high-expression malignanciesr.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| [68Ga]P3 | Experimental | Subjects with suspected or confirmed malignancy will receive an intravenous injection of 68Ga-P3 followed by PET imaging. The subjects will also receive a whole-body 18F-FDG PET/CT scan within a one-week period. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| [68Ga]P3 | Drug | 68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg. |
|
| Measure | Description | Time Frame |
|---|---|---|
| The diagnostic efficacy of 68Ga-P3 PET/CT in the evaluation of malignant tumors | Compare the standardized Uptake Value (SUV) of lesions on 68Ga-P3 and 18F-FDG PET/CT | 1 year |
| The detection efficacy of 68Ga-P3 PET/CT in the evaluation of malignant tumors | Compare the number of lesions detected by 68Ga-P3 and 18F-FDG PET/CT, based on the pathology or clinical follow-up as gold standard. | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| The dosimetry of 68Ga-P3 | Research on the dose distribution of 68Ga-P3 in healthy volunteers and cancer patients by 1-hour dynamic PET/CT acquisition and analyze by the dosimetry software | 1 year |
| Quantitative evaluation of 68Ga-P3 |
Not provided
Inclusion Criteria:
patients with confirmed or suspected cancer; 18F-FDG PET/CT within 1 week; Signed written informed consent
Exclusion Criteria:
Pregnant and lactating women; Female patients plan to become pregnant within 6 months.
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Xing Yang, Dr. | Contact | +861083572928 | yangxing2017@bjmu.edu.cn |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Peking University First Hospital | Recruiting | Beijing | Beijing Municipality | 100034 | China |
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Evaluation of quantitative parameters of 68Ga-P3, such as time-activity curve.
| 1 year |
| Correlation with pathological expression | Analyze PSMA expression at the imaging level in combination with PSMA expression in pathological specimens | 1 year |